| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_eccd894c99fea2d1c0c8735872bb2309 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-105
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-78 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-78
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6887
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1825
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 |
| filingDate |
2018-09-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4d6be134708b065b3adb1095fc5f26aa
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_59e0ea6512115355f477811bc2b2154a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_76f2bd75ec5ba1bdcb10cd0e3f3ec2e5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1101d4c67a6e237a2d1d5d2c0277174b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_914b1fc0727f18807386d94c9020038c |
| publicationDate |
2020-05-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-111163791-A |
| titleOfInvention |
Metabolic biomarkers predicting responsiveness to FGF-18 compounds |
| abstract |
The present invention relates to biomarkers associated with clinical response to FGF-18 compounds before or during cartilage disease treatment. In particular, the present invention relates to specific proteins in blood, serum, synovial fluid or urine useful in the diagnosis and treatment of cartilage diseases. The present invention also discloses specific proteins related to cartilage response to FGF-18 compound treatment and diagnostic tools and kits based on the expression profiles of these proteins. Accordingly, the present invention can be used to predict the effect of FGF-18 compound treatment prior to initiation of treatment with FGF-18 or during treatment. It can be used to select/identify subjects that can be treated with intra-articular administration of FGF-18 compounds. The use of these biomarkers for diagnosis may increase the benefit and reduce the risk of the subject. |
| priorityDate |
2017-09-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |